Dc-Cik
Nasopharyngeal Cancer
Xiaoyi HuangCell therapyPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Nasopharyngeal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
[68ga]ga-nota-rt4 RenJi Hospital | Phase 2/3 | B |
[68ga]ga-nota-t4 RenJi Hospital | Phase 2/3 | B |
[18f]f-resca-rt4 RenJi Hospital | Phase 2/3 | B |
[18F]F-RESCA-T4 RenJi Hospital | Phase 2/3 | B |
DEXAMETHASONE Takeda | Phase 1/2 | CCC |
View all 14 →
Same molecule, other indications
Dc-Cik is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →